## 3 Results
### Outcome  
All treatment modalities were successful in achieving favorable biological outcomes after therapy. Radiographic bone gain (Figure 2) was negligible for flap access procedures (0.11 mm; 95% CI, \(-\)0.56-0.79; \(\mathrm{I}^{2}\): 96%); bone loss (\(-\)0.50 mm; 95% CI, \(-\)1.30-0.30; \(\mathrm{I}^{2}\): 17%) was noted after resective interventions, and 2.34 mm of radiographic bone gain (95% CI, 1.64-3.03; \(\mathrm{I}^{2}\): 91%) was noted following reconstructive treatments. PD reduction for all sets of studies averaged to 3.20 mm (95% CI, 2.41-3.99; Figure 3). Group-based PD reduction resulted in 2.23 mm (95% CI, 0.70-3.76; \(\mathrm{I}^{2}\): 99%) for flap access, 2.25 mm (95% CI, 1.39-3.11; \(\mathrm{I}^{2}\): 73%) for resective interventions, and 3.78 mm (95% CI, 2.96-4.59; \(\mathrm{I}^{2}\): 92%) for reconstructive modalities. All treatment modalities were followed by a small increase in mucosal recession that averaged as 0.89 mm (95% CI, 0.58-1.20; Figure 4). Recession was larger for the flap (1.44 mm; 95% CI, 0.52-2.36; \(\mathrm{I}^{2}\): 84%) and resective approaches (1.28 mm; 95% CI, 0.70-1.85; \(\mathrm{I}^{2}\): 0%) and it was least for the reconstructive group (0.62 mm; 95% CI, 0.29-0.94; \(\mathrm{I}^{2}\): 85%). Four authors reported at least one group of intervention with 100% of implant survival at the last follow-up [26; 31; 36; 38] while survival of other reports ranged between 67% [30] and 98.8% [29]. Overall implant survival rates after treatment of peri-implantitis was of 91% (95% CI, 87-95; Figure 5). Survival rate varied according to treatment modality and averaged as 84% (95% CI, 77-91; \(\mathrm{I}^{2}\): 0%) for the flap access, 90% (95% CI, 82-99; \(\mathrm{I}^{2}\): 92%) for the resective group, and 95% (95% CI, 91-99; \(\mathrm{I}^{2}\): 52.9) for the reconstructive modalities. \begin{table}
\begin{tabular}{c c c c c c c c c c c} \hline \hline  & & \multicolumn{4}{c}{**Treatment Provided**} & \multicolumn{6}{c}{**Outcome Assessed**} \\ \hline
**Study** & **Pre-Treatment** & **Surgical Treatment** & **Post-Treatment** & **Suppepe** & **Retreatment** & **Biological** & **Radigraphic** & **Biological** & **Biological** & **Success** & **Implant Survival** \\
**Reference** & & & & & & & & & & & \\ \hline
**[PERSON] et al. ** & & & & & & & & & &  
\begin{table}
\begin{tabular}{c c c c c c c c c c c c} \hline \hline  & & \multicolumn{4}{c}{**Treatment Provided**} & \multicolumn{6}{c}{**Outcome Assessed**} \\ \hline
**Study** & **Pre-Treatment** & **Sungical Treatment** & **Post-Treatment** & **Sungical Treatment** & **Sungocyte Therapy** & **Retreatment Needed** & **Biological Outcome** & **Radiographic Outcome** & **Biological Outcome** & **Biological Outcome** & **Initial Survival at Last Follow-Up** \\ \hline
**[PERSON] et al. ** & \begin{tabular}{c} Correction of \\ bad-designed \\ prostheses, \\ SBP \\ \end{tabular}  & \begin{tabular}{c} **Resective** \\ bad-designed \\ prostheses, \\ SBP \\ \end{tabular}  & \ \begin{tabular}{c} 3 th and 6 th \\ precur \\ AFP \\ \end{tabular}  & \begin{tabular}{c} 3 th and 6 th \\ precur \\ AFP \\ \end{tabular}  & No & NP & 61\% & 97\% \\ \hline
**Roses-Jansker** & \begin{tabular}{c} **Recontative** \\ PRS removal, FTF, \\ H\({}_{\text{O}}\), Algapore new graft, \\ w/o resomb membrane, \\ pros recovered. \\ \end{tabular}  & \begin{tabular}{c} **Recontative** \\ metronidazoleade \\ (10 days), \\ errors recovered. \\ \end{tabular}  & \begin{tabular}{c} 6 th week, then \\ every 3 \\ errors \\ \end{tabular}  & No & \ \begin{tabular}{c} PD reduction: \\ 3.3 mm control \\ 1.1 mm control. \\ \end{tabular}  & \begin{tabular}{c} Bone gain: \\ 6.7\% \\ -51.1\% \\ \end{tabular}  & 100\% \\ \hline
**[PERSON] et al. ** & \begin{tabular}{c} **Resontative** \\ TRK \\ NRA (no) or NRA + CM \\ control), CAF \\ \end{tabular}  & \ \begin{tabular}{c} every 2 weeks \\ for 2 months, \\ one or month \\ \end{tabular}  & Yes & \begin{tabular}{c} PD reduction: \\ 1.1 mm NRA \\ 25 mm NRA + CM \\ RSC. \\ \end{tabular}